Romero J, Berrendero F, Manzanares J, Pérez A, Corchero J, Fuentes J A, Fernández-Ruiz J J, Ramos J A
Departamento de Bioquímica, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
Synapse. 1998 Nov;30(3):298-308. doi: 10.1002/(SICI)1098-2396(199811)30:3<298::AID-SYN7>3.0.CO;2-6.
Recent studies have demonstrated that the pharmacological tolerance observed after prolonged exposure to plant or synthetic cannabinoids in adult individuals seems to have a pharmacodynamic rather than pharmacokinetic basis, because down-regulation of cannabinoid receptors was assessed in the brain of cannabinoid-tolerant rats. In the present study, we have examined the time-course of cannabinoid receptor down-regulation by analyzing cannabinoid receptor binding, using autoradiography, and mRNA expression, using in situ hybridization, in several brain structures of male adult rats daily exposed to delta9-tetrahydrocannabinol (delta9-THC) for 1, 3, 7, or 14 days. With only the exception of a few number of areas, most of the brain regions exhibited a progressive decrease in cannabinoid receptor binding. Two facts deserve to be mentioned. First, the pattern of this down-regulation process presented significant regional differences in terms of onset of the decrease and magnitude reached. Second, the loss of cannabinoid receptor binding was usually accompanied by no changes in its mRNA expression. Thus, some structures, such as most of the subfields of the Ammon's horn and the dentate gyrus in the hippocampus, exhibited a rapid (it appeared after the first injection) and marked (it reached approximately 30% of decrease after 14 days) reduction of cannabinoid receptor binding as a consequence of the daily delta9-THC administration. However, no changes occurred in mRNA levels. Decreased binding was also found in most of the basal ganglia, but the onset of this reduction was slow in the lateral caudate-putamen and the substantia nigra (it needed at least three days of daily delta9-THC administration), and, in particular, in the globus pallidus (more than 3 days). The magnitude of the decrease in binding was also more moderate, with maximal reductions always less than 28%. No changes were seen in the entopeduncular nucleus and only a trend in the medial caudate-putamen. However, the decrease in binding in some basal ganglia was, in this case, accompanied by a decrease in mRNA levels in the lateral caudate-putamen, but this appeared after 7 days of daily delta9-THC administration and, hence, after the onset of binding decrease. In the limbic structures, cannabinoid receptor binding decreased in the septum nuclei (it needed at least 3 days of daily delta9-THC administration), tended to diminish in the nucleus accumbens and was unaltered in the basolateral amygdaloid nucleus, with no changes in mRNA levels in these last two regions. Binding also decreased in the superficial and deep layers of the cerebral cortex, but only accompanied by trends in mRNA expression. The decrease in binding was initiated promptly in the deep layer (after the first injection) and it reached more than 30% of reduction after 14 days of daily delta9-THC administration, whereas, in the superficial layer, it needed more than 3 days of daily delta9-THC administration and reached less than 30% of reduction. Finally, no changes in binding and mRNA levels were found in the ventromedial hypothalamic nucleus. In summary, the daily administration of delta9-THC resulted in a progressive decrease in cannabinoid receptor binding in most of the brain areas studied, and it was a fact that always occurred before the changes in mRNA expression in those areas where these existed. The onset of the decrease in binding exhibited regional differences with areas, such as most of the hippocampal structures and the deep layer of the cerebral cortex, where the decrease occurred after the first administration. Other structures, however, needed at least 3 days or more to initiate receptor binding decrease. Two structures, the entopeduncular nucleus and the ventromedial hypothalamic nucleus, were unresponsive to chronic delta9-THC administration, whereas others, the medial caudate-putamen and the basolateral amygdaloid nucleus, only exhibited trends.
最近的研究表明,成年个体长期接触植物或合成大麻素后出现的药理学耐受性似乎具有药效学而非药代动力学基础,因为在大麻素耐受大鼠的大脑中评估了大麻素受体的下调情况。在本研究中,我们通过放射自显影分析大麻素受体结合以及通过原位杂交分析mRNA表达,研究了成年雄性大鼠每日暴露于Δ⁹-四氢大麻酚(Δ⁹-THC)1、3、7或14天的情况下,大麻素受体下调的时间进程。在几个脑区进行了上述研究。除少数区域外,大多数脑区的大麻素受体结合呈逐渐下降趋势。有两个事实值得一提。第一,这种下调过程的模式在下降起始时间和达到的幅度方面存在显著的区域差异。第二,大麻素受体结合的丧失通常伴随着其mRNA表达无变化。因此,一些结构,如海马体中阿蒙氏角的大多数亚区和齿状回,由于每日给予Δ⁹-THC,大麻素受体结合迅速(首次注射后出现)且显著下降(14天后下降约30%)。然而,mRNA水平没有变化。在大多数基底神经节中也发现结合减少,但在外侧尾状核-壳核和黑质中这种减少的起始较慢(每日给予Δ⁹-THC至少需要三天),特别是在苍白球中(超过三天)。结合减少的幅度也较为适中,最大减少量始终小于28%。在内侧缰核中未观察到变化,在内侧尾状核-壳核中只有下降趋势。然而,在某些基底神经节中结合减少的同时,外侧尾状核-壳核中的mRNA水平也下降,但这在每日给予Δ⁹-THC 7天后出现,即在结合减少开始之后。在边缘系统结构中,隔核中的大麻素受体结合减少(每日给予Δ⁹-THC至少需要3天),伏隔核中的结合有减少趋势,基底外侧杏仁核中的结合未改变,后两个区域的mRNA水平没有变化。大脑皮层的浅层和深层结合也减少,但仅伴随着mRNA表达的趋势变化。深层结合减少在首次注射后迅速开始(每日给予Δ⁹-THC 14天后减少超过30%),而在浅层,每日给予Δ⁹-THC需要超过3天且减少量小于30%。最后,腹内侧下丘脑核中的结合和mRNA水平未发现变化。总之,每日给予Δ⁹-THC导致所研究的大多数脑区中大麻素受体结合逐渐减少,并且在那些存在mRNA表达变化的区域,这种减少总是在mRNA表达变化之前发生。结合减少的起始在不同区域存在差异,如大多数海马结构和大脑皮层深层,在首次给药后就出现减少。然而,其他结构至少需要3天或更长时间才开始受体结合减少。两个结构,内侧缰核和腹内侧下丘脑核,对慢性给予Δ⁹-THC无反应,而其他结构,内侧尾状核-壳核和基底外侧杏仁核,仅表现出下降趋势。